Establishment Labs Holdings Inc. $ESTA Shares Bought by Tejara Capital Ltd

Tejara Capital Ltd grew its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 22.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 125,294 shares of the company’s stock after acquiring an additional 22,800 shares during the quarter. Establishment Labs makes up approximately 2.1% of Tejara Capital Ltd’s holdings, making the stock its 7th largest position. Tejara Capital Ltd owned 0.43% of Establishment Labs worth $9,131,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ESTA. Truist Financial Corp bought a new position in Establishment Labs during the fourth quarter worth $200,000. Sigma Planning Corp bought a new stake in Establishment Labs during the fourth quarter valued at $350,000. Verdence Capital Advisors LLC bought a new stake in Establishment Labs during the fourth quarter valued at $208,000. NBC Securities Inc. acquired a new stake in shares of Establishment Labs during the fourth quarter worth $272,000. Finally, Choreo LLC acquired a new stake in shares of Establishment Labs during the fourth quarter worth $204,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 330,000 shares of company stock valued at $22,854,538 in the last quarter. 9.99% of the stock is currently owned by company insiders.

Establishment Labs Stock Performance

Shares of ESTA opened at $69.80 on Friday. The firm has a fifty day moving average of $64.67 and a 200-day moving average of $67.32. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -46.85 and a beta of 1.12. The company has a debt-to-equity ratio of 16.82, a quick ratio of 2.00 and a current ratio of 2.96. Establishment Labs Holdings Inc. has a 1 year low of $33.35 and a 1 year high of $83.31.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm’s revenue was up 44.7% on a year-over-year basis. During the same period last year, the business earned ($0.70) EPS. As a group, equities analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Stephens lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Mizuho increased their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Needham & Company LLC lifted their target price on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Establishment Labs has an average rating of “Moderate Buy” and an average price target of $87.14.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.